z-logo
open-access-imgOpen Access
Photodynamic therapy for multi-resistant cutaneous Langerhans cell histiocytosis
Author(s) -
Valérie Failla,
Odile Wauters,
Marie Caucanas,
Nazli NikkelsTassoudji,
Arjen Nikkels
Publication year - 2010
Publication title -
rare tumors
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.285
H-Index - 15
eISSN - 2036-3613
pISSN - 2036-3605
DOI - 10.4081/rt.2010.e34
Subject(s) - medicine , langerhans cell histiocytosis , photodynamic therapy , vinblastine , scalp , nitrogen mustard , dermatology , histiocytosis , langerhans cell , pathology , chemotherapy , surgery , cyclophosphamide , immunology , antigen , chemistry , disease , organic chemistry
Langerhans cell histiocytosis is a rare group of proliferative disorders. Beside cutaneous involvement, other internal organs can be affected. The treatment of cutaneous lesions is difficult and relies on topical corticosteroids, carmustine, nitrogen mustard, and photochemotherapy. Systemic steroids and vinblastine are used for recalcitrant skin lesions. However, some cases fail to respond. An 18-month old boy presented a CD1a+, S100a+ Langerhans cell histocytosis with cutaneous and severe scalp involvement. Topical corticosteroids and nitrogen mustard failed to improve the skin lesions. Systemic corticosteroids and vinblastine improved the truncal involvement but had no effect on the scalp lesions. Methyl-aminolevulinate (MAL) based photodynamic therapy (PDT) resulted in a significant regression of the scalp lesions. Control histology revealed an almost complete clearance of the tumor infiltrate. Clinical follow-up after six months showed no recurrence. Although spontaneous regression of cutaneous Langerhans cell histiocytosis is observed, the rapid effect of photodynamic therapy after several failures of other treatment suggests that photodynamic therapy was successful. As far as we know this is the first report of photodynamic therapy for refractory skin lesions. Larger series are needed to determine whether photodynamic therapy deserves a place in the treatment of multiresistant cutaneous Langerhans cell histiocytosis

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom